These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 12077256)
1. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. Birle D; Bottini N; Williams S; Huynh H; deBelle I; Adamson E; Mustelin T J Immunol; 2002 Jul; 169(1):286-91. PubMed ID: 12077256 [TBL] [Abstract][Full Text] [Related]
2. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. Freeburn RW; Wright KL; Burgess SJ; Astoul E; Cantrell DA; Ward SG J Immunol; 2002 Nov; 169(10):5441-50. PubMed ID: 12421919 [TBL] [Abstract][Full Text] [Related]
3. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Shan X; Czar MJ; Bunnell SC; Liu P; Liu Y; Schwartzberg PL; Wange RL Mol Cell Biol; 2000 Sep; 20(18):6945-57. PubMed ID: 10958690 [TBL] [Abstract][Full Text] [Related]
4. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Xu Z; Stokoe D; Kane LP; Weiss A Cell Growth Differ; 2002 Jul; 13(7):285-96. PubMed ID: 12133897 [TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor PTEN regulates T cell survival and antigen receptor signaling by acting as a phosphatidylinositol 3-phosphatase. Wang X; Gjörloff-Wingren A; Saxena M; Pathan N; Reed JC; Mustelin T J Immunol; 2000 Feb; 164(4):1934-9. PubMed ID: 10657643 [TBL] [Abstract][Full Text] [Related]
6. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863 [TBL] [Abstract][Full Text] [Related]
7. Lipid phosphatases in the regulation of T cell activation: living up to their PTEN-tial. Seminario MC; Wange RL Immunol Rev; 2003 Apr; 192():80-97. PubMed ID: 12670397 [TBL] [Abstract][Full Text] [Related]
8. Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells. Freeley M; Park J; Yang KJ; Wange RL; Volkov Y; Kelleher D; Long A Cell Signal; 2007 Dec; 19(12):2444-57. PubMed ID: 17826953 [TBL] [Abstract][Full Text] [Related]
9. Signaling pathways of D3-phosphoinositide-binding kinases in T cells and their regulation by PTEN. Seminario MC; Wange RL Semin Immunol; 2002 Feb; 14(1):27-36. PubMed ID: 11884228 [TBL] [Abstract][Full Text] [Related]
10. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Wishart MJ; Dixon JE Trends Cell Biol; 2002 Dec; 12(12):579-85. PubMed ID: 12495846 [TBL] [Abstract][Full Text] [Related]
11. PTEN permits acute increases in D3-phosphoinositide levels following TCR stimulation but inhibits distal signaling events by reducing the basal activity of Akt. Seminario MC; Precht P; Bunnell SC; Warren SE; Morris CM; Taub D; Wange RL Eur J Immunol; 2004 Nov; 34(11):3165-75. PubMed ID: 15468057 [TBL] [Abstract][Full Text] [Related]
13. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Koul D; Jasser SA; Lu Y; Davies MA; Shen R; Shi Y; Mills GB; Yung WK Oncogene; 2002 Apr; 21(15):2357-64. PubMed ID: 11948419 [TBL] [Abstract][Full Text] [Related]
14. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356 [TBL] [Abstract][Full Text] [Related]
15. Regulation of the PTEN phosphatase. Gericke A; Munson M; Ross AH Gene; 2006 Jun; 374():1-9. PubMed ID: 16675164 [TBL] [Abstract][Full Text] [Related]
16. Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN. Gao P; Wange RL; Zhang N; Oppenheim JJ; Howard OM Blood; 2005 Oct; 106(8):2619-26. PubMed ID: 15994292 [TBL] [Abstract][Full Text] [Related]
17. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Maehama T; Dixon JE Trends Cell Biol; 1999 Apr; 9(4):125-8. PubMed ID: 10203785 [TBL] [Abstract][Full Text] [Related]
18. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Han SY; Kato H; Kato S; Suzuki T; Shibata H; Ishii S; Shiiba K; Matsuno S; Kanamaru R; Ishioka C Cancer Res; 2000 Jun; 60(12):3147-51. PubMed ID: 10866302 [TBL] [Abstract][Full Text] [Related]
19. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Asano T; Yao Y; Zhu J; Li D; Abbruzzese JL; Reddy SA Oncogene; 2004 Nov; 23(53):8571-80. PubMed ID: 15467756 [TBL] [Abstract][Full Text] [Related]
20. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Yi HK; Kim SY; Hwang PH; Kim CY; Yang DH; Oh Y; Lee DY Biochem Biophys Res Commun; 2005 May; 330(3):760-7. PubMed ID: 15809062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]